Work With Data
Profile
user
live In the news:
Ozempic is growing in popularity -- it's also sending people to the ER / Novo Nordisk scores major legal win that bars many compounded versions of Wegovy, Ozempic / Ozempic maker spending more than $3m to lobby fat cats in Washington as weight-loss drugs faces regulatory decisions / Lilly Soars After Pill Shows Its as Good as Ozempic.com / Pfizer just had a big setback in its race for an Ozempic competitor / An Ozempic successor falls short, Eli Lilly's GLP-1 pill, and senators grill RFK: Pharma news roundup / Viking Therapeutics closer to bringing its Ozempic competitor to market / Wegovy's price cut, Amgen's Ozempic competitor, and Big Pharma's tax cut: Pharma news roundup / Woman on Ozempic switched to chia seeds, this was the result

Ozempic

Updated: 43d ago

Ozempic is a company. It is a private company in the United States. It is part of the Health Care sector.

Key facts

  • country: United States
  • employees: 40 people
  • revenues: 4M $
  • company type: private
  • sector: Health Care
  • ESG score: 76.95 / 100
plus See more facts

Extract data

Download datasets about Ozempic:

dataset Dataset of stocks from Ozempic:

Ozempic is one of the companies in the United States, companies in Health Care and 3,456,808 companies in our database.

Talking Points

  • Ozempic® (semaglutide) injection for Type 2 Diabetes
  • Ozempic® (semaglutide) injection is a once-weekly GLP-1 RA medicine that, along with diet and exercise, may help improve blood sugar in adults with type 2 diabetes. Read Important Safety Information, including Boxed Warning.

This dashboard is based on data from: YAHOO-FIN, YFINANCE, Twitter.

This content is available under the CC BY 4.0 license.